B GROUP INC
Q1 2026 Form 13-F
DALLAS, KANSAS
CIK 0002043476
· Institutional investment manager
$134.9M Reported Value Total
Reported value
$134.9M
Quarter over quarter
-24.6%
Holdings
20
Top-10 concentration
81.1%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
David Chang
Chief Compliance Officer
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2026 13F record
Q1 2026 13F filing summary
| Period of report | March 31, 2026 |
|---|---|
| Filed | May 15, 2026 |
| Form | 13F-HR |
| Reported value | $134.9M |
| Positions | 20 |
| Change in reported value | -0.4% |
| New positions | 5 |
| Exited positions | 0 |
| Position turnover | 25.0% |
| Top-10 concentration | 81.1% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
18 | $213.0M |
|
Q1 2026 13F
Filed May 15, 2026
|
20 | $134.9M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
15 | $135.4M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
17 | $135.9M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
15 | $129.9M |
|
Q1 2025 13F
Filed May 15, 2025
|
17 | $116.7M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
18 | $163.6M |
Top 20 holdings · Q1 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ADMA ADMA BIOLOGICS INC | $28.9M | 21.43% |
| 2 | PALI PALISADE BIO INC | $20.0M | 14.81% |
| 3 | PRAX PRAXIS PRECISION MEDICINES I | $10.7M | 7.94% |
| 4 | CLLS CELLECTIS S A | $10.4M | 7.71% |
| 5 | ZLAB ZAI LAB LTD | $8.5M | 6.28% |
| 6 | TSHA TAYSHA GENE THERAPIES INC | $8.0M | 5.97% |
| 7 | NRXP NRX PHARMACEUTICALS INC | $6.4M | 4.74% |
| 8 | GPCR STRUCTURE THERAPEUTICS INC | $6.1M | 4.56% |
| 9 | IOVA IOVANCE BIOTHERAPEUTICS INC | $5.3M | 3.9% |
| 10 | SYRE SPYRE THERAPEUTICS INC | $5.0M | 3.74% |
| 11 | DRUG BRIGHT MINDS BIOSCIENCES INC | $4.9M | 3.65% |
| 12 | ASMB ASSEMBLY BIOSCIENCES INC | $4.9M | 3.61% |
| 13 | AURA AURA BIOSCIENCES INC | $4.0M | 2.96% |
| 14 | ORKA ORUKA THERAPEUTICS INC | $3.7M | 2.73% |
| 15 | SGHT SIGHT SCIENCES INC | $3.7M | 2.71% |
| 16 | RARE ULTRAGENYX PHARMACEUTICAL IN | $2.8M | 2.1% |
| 17 | APGE APOGEE THERAPEUTICS INC | $631.3K | 0.47% |
| 18 | FHTX FOGHORN THERAPEUTICS INC | $487.6K | 0.36% |
| 19 | SLNO SOLENO THERAPEUTICS INC | $251.1K | 0.19% |
| 20 | REPL REPLIMUNE GROUP INC | $198.9K | 0.15% |
Values as reported on the Q1 2026 Form 13F. Every position is in the holdings table below.